Ernexa Therapeutics (ERNAW) Receivables - Net (2010 - 2021)

Ernexa Therapeutics (ERNAW) has 12 years of Receivables - Net data on file, last reported at $684000.0 in Q4 2021.

• Quarterly Receivables - Net changed N/A year-over-year to $684000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $684000.0 (changed N/A YoY) and the FY2021 annual result came in at $684000.0, changed N/A from the prior year.
• Receivables - Net advanced to $684000.0 in Q4 2021, from $24918.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $1.8 million in Q1 2017 to a low of $24918.0 in Q1 2021.
• A 5-year average of $762182.4 and a median of $746500.0 in 2017 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2020 — Receivables - Net jumped 142.41% — and 2021, when it sank 93.49%.
• Tracing ERNAW's Receivables - Net over 5 years: stood at $714000.0 in 2017, then jumped by 60.08% to $1.1 million in 2018, then rose by 4.55% to $1.2 million in 2019, then slumped by 88.95% to $132000.0 in 2020, then surged by 418.18% to $684000.0 in 2021.
• The last three Receivables - Net figures came in at $684000.0 (Q4 2021), $24918.0 (Q1 2021), and $132000.0 (Q3 2020), per Business Quant data.